中文
EN
News Center
News Center
Advancing into a New Chapter: Viwit Pharma Officially Launches Frontier Exploration in Targeted Gene and Cell Therapies
Author：
VIWIT
Release Time：
2026-01-19
In Viwit Pharma’s journey of innovation-driven growth, continuous advancement and the expansion of scientific boundaries are essential to sustaining long-term vitality.
Guided by deep respect for life and a spirit of scientific inquiry, Viwit Pharma formally announces the launch of a systematic exploration in the frontier of innovative biological therapies. This initiative aims to build early scientific foundations in emerging modalities such as targeted gene therapy and in vivo cell therapy.
At the core of this effort is a targeted lipid nanoparticle (tLNP) technology platform, built upon our strengths in MAP (Medicinal Chemistry + AI + Phage Display) targeted molecular design and optimization. The platform is designed to overcome the limitations of conventional delivery systems by integrating proprietary ionizable lipids with unique targeted miniprotein design capabilities, with the goal of developing next-generation delivery systems that can reach target cells with greater precision.
Based on this platform, our initial research will focus on two directions with transformative potential:
- tLNP–mRNA technology: Exploring the possibility of directly generating therapeutic cells in vivo via mRNA/circRNA (such as in vivo CAR-T cells), offering new paradigms for more accessible and scalable cell therapy. This approach will be investigated for applications in autoimmune diseases and cancer immunotherapy.
- tLNP–siRNA technology: Investigating its application in diseases driven by specific genetic factors, expanding the therapeutic potential of oligonucleotide medicines. This technology aims to enable targeted delivery beyond the liver, allowing precise intervention against disease-causing genes that are difficult to reach with conventional drugs—particularly in chronic diseases, rare diseases, and genetically related disorders.
We are fully aware that frontier exploration is accompanied by uncertainty and challenges. This initiative represents a measured step forward under Viwit Pharma’s strategy of “deep scientific insight and a science-first philosophy,” reflecting our proactive engagement with future therapeutic paradigms and our commitment to long-term investment. Leveraging our solid capabilities in CMC development and industrialization, we will advance these novel drug programs with a scientific, pragmatic, and disciplined approach.
Innovation for a better life. With openness and rigor, Viwit Pharma will continue to build strength within the global wave of innovation—laying the groundwork today and preparing to contribute to tomorrow’s health solutions.